← Back to all signals
RESEARCH PAPER ANALYSIS

The effect of exposure to radiofrequency fields on cancer risk in the general and working population: A systematic review of human observational studies - Part II: Less researched outcomes.

AI interpretation is pending for this paper.

Open original publication →
PMID39904670
JournalEnvironment international
Publication Date2025-01-11
Ingested2026-08-02 12:03 AM
EXECUTIVE SUMMARY

What the AI sees

Not AI summarized yet.

WHY IT MATTERS

Research significance

Pending deeper interpretation.

ABSTRACT

Source abstract

BACKGROUND: In the framework of the World Health Organization assessment of health effects of exposure to radiofrequency electromagnetic fields (RF-EMF), we have conducted a systematic review of human observational studies on the association between exposure to RF-EMF and risk of neoplastic diseases. Due to the extremely large number of included exposure types/settings and neoplasm combinations, we decided to present the review findings in two separate papers. In the first one we addressed the most investigated exposure-outcome pairs (e.g. glioma, meningioma, acoustic neuroma in relation to mobile phone use, or risk childhood leukemia in relation to environmental exposure from fixed-site transmitters) (Karipidis et al., 2024). Here, we report on less researched neoplasms, which include lymphohematopoietic system tumours, thyroid cancer and oral cavity/pharynx cancer, in relation to wireless phone use, or occupational RF exposure. METHODS: Eligibility criteria: We included cohort and case-control studies of neoplasia risks in relation to three types of exposure to RF-EMF: 1. exposure from wireless phone use; 2. environmental exposure from fixed-site transmitters; 3. occupational exposures. In the current paper, we focus on less researched neoplasms including leukaemia, non-Hodgkin's lymphoma and thyroid cancer in mobile phone users; lymphohematopoietic system tumours and oral cavity/pharynx cancer in exposed workers. We focussed on investigations of specific neoplasms in relation to specific exposure sources (termed exposure-outcome pair, abbreviated E-O pairs), noting that a single article may address multiple E-O pairs. INFORMATION SOURCES: Eligible studies were identified by predefined literature searches through Medline, Embase, and EMF-Portal. Risk-of-bias (RoB) assessment: We used a tailored version of the Office of Health Assessment and Translation (OHAT) RoB tool to evaluate each study's internal validity. Then, the studies were classified into three tiers according to their overall potential for bias (low, moderate and high) in selected, predefined and relevant bias domains. DATA SYNTHESIS: We synthesized the study results using random effects restricted maximum likelihood (REML) models. Evidence assessment: Confidence in evidence was assessed according to the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach. RESULTS: We included 26 articles, which were published between 1988 and 2019, with participants from 10 countries, reporting on 143 different E-O pairs, including 65 different types of neoplasms. Of these, 19 E-O pairs satisfied the criteria for inclusion in quantitative syntheses of the evidence regarding the risks of leukaemia, non-Hodgkin's lymphoma or thyroid cancer in relation to mobile phone use, and the risks of lymphohematopoietic system tumours or oral cavity/pharynx cancer following occupational exposure to RF-EMF. RF-EMF exposure from mobile phones (ever or regular use vs no or non-regular use) was not associated with an increased risk of leukaemia [meta-estimate of the relative risk (mRR) = 0.99, 95 % CI 0.91-1.07, 4 studies), non-Hodgkin's lymphoma (mRR = 0.99, 95 % CI = 0.92-1.06, 5 studies), or thyroid cancer (mRR = 1.05, 95 % CI = 0.88-1.26, 3 studies). Long-term (10 + years) mobile phone use was also not associated with risk of leukaemia (mRR = 1.03, 95 % CI 0.85-1.24, 3 studies), non-Hodgkin lymphoma (mRR = 0.99, 95 % CI 0.86-1.15, 3 studies), or thyroid cancer (no pooled estimate given the small number of studies). There were not sufficient studies of any specific neoplasms to perform dose-response meta-analyses for either cumulative call time or cumulative number of calls; individual studies did not show statistically significant associations between lifetime intensity of mobile phone use and any specific neoplasm. Occupational RF-EMF exposure (exposed vs unexposed) was not associated with an increased risk of lymphohematopoietic system tumours (mRR = 1.03, 95 % CI = 0.87-1.28, 4 studies) or oral cavity/pharynx cancer (mRR = 0.68, 95 % CI 0.42-1.11, 3 studies). There were not sufficient studies of any specific neoplasms to perform meta-analysis on the intensity or duration of occupational RF-EMF exposure; individual studies did not show statistically significant associations with either of those exposure metrics and any specific neoplasms. The small number of studies, and of exposed cases in some instances, hampered the assessment of the statistical heterogeneity in findings across studies in the meta-analyses. Based on the summary risk of bias, most studies included in the quantitative evidence syntheses were classified at moderate risk of bias. The most critical issue was exposure information bias, especially for occupational studies where the exposure characterization was rated at high risk of bias for all included studies. Outcome information bias was an issue in mortality-based occupational cohort studies investigating non-rapidly fatal neoplasms. Further, the healthy subscriber effect, and (at a lesser extent) the healthy worker effect, were identified as plausible explanations of the decreased risks observed in some studies. The association of RF-EMF exposure from wireless phone use, or workplace equipment/devices, with other important neoplasms was reported by only one or two studies per tumour, so no quantitative evidence syntheses were conducted on these outcomes. It is noted that there were generally no statistically significant exposure-outcome associations for any combinations, independently of the exposure metric and level, with a few studies reporting decreased risks (especially for smoking-related cancers). There was only one study which assessed the effect of RF-EMF exposure from fixed-site transmitters on less researched neoplasms and it reported no statistically significant associations between exposure from base stations and risk of lymphomas overall, lymphoma subtypes, or chronic lymphatic leukaemia in adults. CONCLUSIONS: For near field RF-EMF exposure to the head from mobile phones, there was low certainty of evidence that it does not increase the risk of leukaemia, non-Hodgkin's lymphoma or thyroid cancer. For occupational RF-EMF exposure, there was very low certainty of evidence that it does not increase the risk of lymphohematopoietic system tumours or oral cavity/pharynx cancer. There was not sufficient evidence to assess the effect of whole-body far-field RF-EMF exposure from fixed-site transmitters (broadcasting antennas or base stations), or the effect of RF-EMF from any source on any other important neoplasms. OTHER: This project was commissioned and partially funded by the World Health Organization (WHO). Co-financing was provided by the New Zealand Ministry of Health; the Istituto Superiore di Sanità in its capacity as a WHO Collaborating Centre for Radiation and Health; and ARPANSA as a WHO Collaborating Centre for Radiation Protection. REGISTRATION: PROSPERO CRD42021236798. Published protocol: [(Lagorio et al., 2021) DOI https://doi.org/10.1016/j.envint.2021.106828].

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 [The role of neuroprotection in treating oculomotor neuropathy in a child following endoscopic cystocisternostomy]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova 57.6 2 Rivaroxaban prophylaxis and catheter-related thrombosis risk in ambulatory gynecological cancer patients: a retrospective cohort study. Thrombosis journal 76.9 3 Mesenchymal transition as a potential mechanism of late immune evasion in neuroblastoma: a case of late relapse after allogeneic hematopoietic stem cell transplantation. World journal of surgical oncology 88.37 4 Gold Nanoparticles in Retinoblastoma: A Promising Approach for Diagnosis and Treatment. Ocular oncology and pathology 76.5 5 Pars Plana Vitrectomy for Retinal Detachment or Vitreous Haemorrhage after Retinoblastoma Regression: A 20-Year Single-Centre Experience. Ocular oncology and pathology 63.1 6 A Novel Protein Corona-Based Secretome Profiling Assisting Cell Multiomics Analysis. Analytical chemistry 49.7 7 Trefoil Family Factor 1 Expression in the Indian Cohort of Treatment-Naïve Retinoblastoma. Ocular oncology and pathology 66.14 8 mTOR inhibitor everolimus versus conventional chemotherapy in pediatric low-grade gliomas. American journal of cancer research 83.3 9 The scPagwas analysis of single-cell sequencing combined with Bayesian deconvolution with SMR Reveals Tumor Heterogeneity and Predicts Immunotherapy Response in Neuroblastoma. Journal of Cancer 67.34 10 Early Prediction of Cardiomyopathy in Pediatric Cancer Survivors Using Echocardiographic Video-Based Deep Learning. Echocardiography (Mount Kisco, N.Y.) 57.5 11 Novel Compound Heterozygous RECQL4 Pathogenic Variants and Associated Phenotypes in a Chinese Patient With Rothmund-Thomson Syndrome: Case Report and Literature Review. Molecular genetics & genomic medicine 47.5 12 Self-Conscious Emotions and Social Isolation Among Young Adult Cancer Survivors. Psycho-oncology 66.0 13 Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma. ESMO open 71.84 14 Fertility preservation counselling in women with cancer: knowledge, preferences, and unmet needs from a cross-sectional survey. Frontiers in endocrinology 66.1 15 Risk prediction model for pegaspargase-associated severe coagulopathy and blood product costs: a single-center retrospective cohort study. Frontiers in pharmacology 63.9 16 The relationship between symptoms of adenomyosis and current ultrasonographic diagnostic criteria. Frontiers in endocrinology 62.4 17 Feasibility of exercise training to address corticosteroid-induced changes in adolescents aged 10+ with lymphoma or leukemia during the first eight weeks of treatment: a pilot study. Frontiers in pediatrics 82.84 18 A predictive model for cytarabine syndrome-associated febrile episodes in children with acute lymphoblastic leukemia. Frontiers in pediatrics 67.4 19 The role of personalised medicine in treating high-risk neuroblastoma in paediatric patients. Oncology reviews 74.0 20 Incidence, severity, and risk factors of platinum-induced ototoxicity in pediatric oncology patients: A multi-center retrospective study. International journal of pediatric otorhinolaryngology 80.72 21 Intracranial Extension of Pott's Puffy Tumor in a Child: CT and MRI Findings. Revista da Sociedade Brasileira de Medicina Tropical 28.5 22 Detecting Isolated Multifocal Leptomeningeal Metastases With 18F-MFBG PET/CT in a Pediatric Patient With High-risk Neuroblastoma. Clinical nuclear medicine 56.4 23 Unusual Isolated Thymic Relapse of Neuroblastoma Detected By 123I-mIBG Scintigraphy in a Pediatric Patient. Clinical nuclear medicine 55.62 24 A Tale of 3 Tracers: Contrasting Uptake Patterns of 18F-FDG, 68Ga-DOTATATE, and 18F-MFBG in a Pediatric Neuroblastoma Patient. Clinical nuclear medicine 57.1 25 Clinical Diagnostic and Prognostic Evaluation of miR-136-5p in Children with Severe Pneumonia: A Case-Control and Cohort Study. Journal of visualized experiments : JoVE 70.8 26 Parents' and health professionals' perspectives on supporting physical activity among children undergoing cancer treatment: A qualitative interview study. European journal of oncology nursing : the official journal of European Oncology Nursing Society 62.74 27 Tests of the testes: markers of testicular function after treatment for pediatric hematological malignancies. The Journal of clinical endocrinology and metabolism 50.74 28 Checkpoint blockade before allogeneic transplantation in pediatric lymphoma warrants a dedicated safety strategy. Comment on: "Immune checkpoint therapy in pediatric and adolescent lymphomas". Haematologica 52.74 29 Forty-Two Cases of Pediatric Giant Cell Tumor of Bone: Insights From a 25-Year Multi-Institutional Cohort. Journal of pediatric orthopedics 63.1 30 Impact of Childbearing and Breastfeeding on Breast Density Change, and Subsequent Breast Cancer Risk in Postmenopausal Women: A Mediation Analysis. International journal of cancer 58.4 31 Neuropathological findings in 2068 individuals with drug-resistant epilepsy based on updated classification systems: A multicenter retrospective cohort study from China. Epilepsia 65.16 32 Clinical Impact of Busulfan Pharmacokinetic Monitoring in Pediatric Allogeneic Transplants: Perspectives from A Transplant Center in A Low- and Middle- Income Country. Pediatric hematology and oncology 63.4
PATIENT-FRIENDLY SUMMARY

The effect of exposure to radiofrequency fields on cancer risk in the general and working population: A systematic review of human observational studies - Part II: Less researched outcomes.

For education only—not personal medical advice.

Before you continue

AI-assisted research information

Neurocompute uses AI to summarize scientific papers, interpret research signals, and suggest relevant reference links. AI-generated content can be incomplete, misleading, or wrong, and generated links may be irrelevant or unavailable.

Our reviewed outputs have performed strongly to date, but past accuracy is not a guarantee. Verify summaries, scores, claims, and links against the original publication before relying on them.

This platform is for research and education only. It does not provide medical advice, diagnosis, treatment recommendations, or clinical guidance.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic